Eli Lilly and Company
LLY
$734.57
-$16.88-2.25%
NYSE
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 11.11B | 10.59B | 8.37B | 7.34B | 6.14B |
| Total Depreciation and Amortization | 1.83B | 1.77B | 1.67B | 1.61B | 1.57B |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 3.38B | 1.85B | 2.33B | 1.08B | 941.80M |
| Change in Net Operating Assets | -7.00B | -5.39B | -6.33B | -5.53B | -4.97B |
| Cash from Operations | 9.32B | 8.82B | 6.03B | 4.51B | 3.68B |
| Capital Expenditure | -5.58B | -5.06B | -4.63B | -4.25B | -3.77B |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -947.70M | -947.70M | -1.99B | -1.99B | -1.04B |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -4.95B | -3.30B | -3.68B | -3.14B | -2.83B |
| Cash from Investing | -11.48B | -9.30B | -10.31B | -9.38B | -7.64B |
| Total Debt Issued | 11.43B | 11.42B | 16.01B | 11.14B | 11.14B |
| Total Debt Repaid | 840.10M | -2.52B | -5.56B | -970.90M | -3.71B |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -3.70B | -2.50B | -446.10M | 0.00 | 0.00 |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -4.86B | -4.68B | -4.53B | -4.38B | -4.22B |
| Other Financing Activities | -787.10M | -490.60M | -476.70M | -436.20M | -443.80M |
| Cash from Financing | 2.92B | 1.23B | 5.00B | 5.36B | 2.77B |
| Foreign Exchange rate Adjustments | -129.30M | -296.70M | 261.10M | 39.50M | 108.30M |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 633.10M | 449.80M | 988.20M | 529.10M | -1.09B |